Clinical Advances in Prostate Cancer

Androgen deprivation therapy (ADT) has been the standard of care for patients with advanced prostate cancer; however, a majority of patients on hormonal therapy become unresponsive to treatment after an initial response.

Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer (mCRPC).

The explosion of new drugs for the treatment of castration-resistant prostate cancer (CRPC) is a welcome advance, but raises questions about how best to sequence these drugs with standard docetaxel chemotherapy.

Therapeutic options have grown considerably in recent years for men with metastatic, castration-resistant prostate cancer (mCRPC), with studies currently looking to combine these new options.

Circulating tumor cells (CTCs) have been recognized as a potential source of prostate cancer seeding to distant metastatic sites (typically bone) for over a century, and with ongoing improvements in isolation and characterization methodology, CTCs are now being more rigorously investigated as potential predictive biomarkers in men with mCRPC.